Replies to post #12225 on Mymetics Corp (MYMX)

[bow-tie]

So we know that the formulation of P467-CRM Montanide induced higher serum lgG antibody tilers, compared with P467-CRM Alum.

The formulation P467-CRM-Montanide has recently been examined in a toxicology study and shown no signs of toxicity or inflammation when evaluated in dogs and rats (data not shown). A doseescalating study, starting with 10 µg of the formulation, is being planned to be evaluated in a phase-Ib/II clinical trial enrolling Her-2/neu overexpressing cancer patients

Do you think that etherna is using this theory?

https://link.springer.com/content/pdf/10.1186%2Fs12885-017-3098-7.pdf